Congratulations to TYK Medicines, Inc (2410.HK) on its Successful Listing

Congratulations to TYK Medicines, Inc (2410.HK) on its successful listing on the Mainboard of HKSE on 20 August 2024.

 

TYK Medicines, Inc (“TYK”) is a clinical-stage biopharmaceutical company committed to the discovery, acquisition, development and commercialization of differentiated targeted therapies to address unmet medical needs in cancer treatment. Since TYK inception in 2017, TYK has built a pipeline with 11 drug candidates, including Core Product TY-9591, six clinical stage products, and four preclinical stage or early clinical development stage products.

 

With regard to this listing application, AVISTA Group is honoured to be engaged in providing valuation analysis in connection with the fair value of preferred shares, impairment test of intangible assets, fair value of RSU and property investment.

 

Congratulations again to TYK Medicines, Inc (2410.HK) on its successful listing. The issue price is HKD12.10 per share and the amount of funds raised is HKD579 million.